Physician
Phi Life Sciences LLC
Phi Life Sciences LLC was paid $375K by Medicaid between Jul 2018 and Oct 2024, across 22 billing codes. Its largest line is 87637, Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV — 54% of everything it billed.
33Billing provider infoPHI LIFE SCIENCES LLC
CHARLESTON, SC 29403
CHARLESTON, SC 29403
33aNPI1437605615assigned 08/29/2016
33bProvider typeMolecular Genetic Pathology (Pathology) Physician
28Total paid$375K
24GClaims7,972
24DCodes billed22
24AFirst – last monthJul 2018 – Oct 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 50 | $0.00 | |
| 2019 | 252 | $4K | |
| 2022 | 5,683 | $157K | |
| 2023 | 1,481 | $183K | |
| 2024incomplete | 506 | $30K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 54% | 1,732 | 1,105 | $201K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 30% | 1,207 | 1,078 | $111K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 7.0% | 1,975 | 1,452 | $26K |
| 86413 | 6.2% | 416 | 357 | $23K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.3% | 772 | 392 | $5K |
| 81226 | <1% | 116 | 104 | $1K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 74 | 63 | $972.94 |
| 86409 | <1% | 149 | 137 | $971.25 | |
| 81225 | <1% | 141 | 129 | $662.33 | |
| 81406 | <1% | 101 | 91 | $644.97 | |
| 81479 | Unlisted molecular pathology procedure | <1% | 233 | 42 | $600.00 |
| 81335 | <1% | 141 | 129 | $524.44 |
10 more codes
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHURST, SAWAN (CEO)
| Provider | Location | Paid |
|---|---|---|
| Phi Life Sciences LLC | College Park, MD | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.